Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq Other stock markets 01:30:00 21/06/2025 am IST			5-day change	1st Jan Change
126.55 ^USD	-0.60%		+1.23%	-7.29%

20/06	Neurocrine Biosciences, Inc. Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGreZZA®? (valbenazine) Capsules in Older Adults with Tardive Dyskinesia	CI
12/06	NetraMark Holdings Inc. Announces New Publication on AI/ML Use in Clinical Trials, Alongside Authors from Leading Global Regulatory Organizations	CI

Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM

Published on 14/05/2024 at 23:50

Presenter Speech
Tazeen Ahmad (Analysts)

Everybody, thanks for joining us for our next session. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm 1 of the senior SMID biotech

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGreZZA®? (valbenazine) Capsules in Older Adults with Tardive Dyskinesia	20/06	CI
NetraMark Holdings Inc. Announces New Publication on AI/ML Use in Clinical Trials, Alongside Authors from Leading Global Regulatory Organizations	12/06	CI
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer	10/06	MT
Neurocrine Biosciences Appoints Lewis Choi As Chief Information Officer	10/06	RE
Neurocrine Biosciences, Inc. Announces the Appointment of Lewis Choi as Chief Information Officer, Effective June 9, 2025	10/06	CI
Nxera Pharma Gets $15 Million Milestone Payment as Schizophrenia Drug Enters Phase 3	03/06	MT
Nxera Pharma to Receive USD 15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568	03/06	CI
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says	02/06	MT
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGreZZA (valbenazine) Capsules	02/06	CI
Nxera Pharma Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025	29/05	CI
Neurocrine Reports Positive Data in Mid-Stage Schizophrenia Trial	29/05	MT
Neurocrine Biosciences, Inc. Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025	29/05	CI
Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11:30 AM	22/05
Neurocrine Biosciences, Inc. Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia	16/05	CI
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 Cahtalyst?? Pediatric Study At Pediatric Endocrine Society 2025 Annual Meeting	16/05	CI
Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures	16/05	MT
Neurocrine Biosciences, Inc. Announces New Data from the Phase 3 CAHtalyst Adult and Pediatric Studies of Chenessity	16/05	CI
Neurocrine Biosciences, Inc. Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia	15/05	CI
Neurocrine Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 11:20 AM	13/05
Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst?? Pediatric Study	08/05	CI
Neurocrine Reports Late Stage Data Of Crenessity	08/05	RE
Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing	08/05	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $152 From $137, Buy Rating Kept	06/05	MT
BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating	06/05	MT
RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating	06/05	MT